Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Arrayit Corporation
  6. News
  7. Summary
    ARYC   US04269N1072

ARRAYIT CORPORATION

(ARYC)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arrayit Corporation Nationwide Allergy Testing Network Doubles to More than 400 Healthcare Clinics

02/11/2019 | 05:31am EST

Sunnyvale, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports that its nationwide allergy testing consortium has more than doubled in the past six months to 410 medical clinics. The rapidly expanding network using the company’s powerful finger stick allergy testing services comprises 33 of the 48 continuous United States, with single clinics staffing as many as 70 doctors in the Northeast, Southeast, Midwest, South, Southwest, Pacific and Pacific Northwest regions. Arrayit allergy testing services assist doctors in diagnosing and treating allergy and asthma, which impact up to 60 million Americans annually. Anti-aging, back pain and sciatica, chiropractic care, dermatology, digestive health, ear nose and throat (ENT), family medicine, gastroenterology, health and beauty, immunology, integrative medicine, internal medicine, obesity, obstetrics and gynecology (OB-GYN), pain relief, pediatrics, personalized medicine, preventative medicine, primary care, rehabilitation, sinus, spinal care, urgent care, weight loss, wellness and women's health are among the specialties included in Arrayit’s nationwide network. 

Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding approval of a major product line, fulfilled an FDA clinical instrumentation contract, received approval for in-store promotions by a major retailer, announced allergy testing partnerships with major allergy therapeutics providers, received approval for direct Medicare billing by the Centers for Medicare and Medicaid Services, launched the Patient Data Solutions allergy portal for doctors and clinics, celebrated 25 years of company operations, announced an allergy testing services agreement with a major health and wellness provider, provided a letter to shareholders from the company’s Chief Executive Officer, aced four consecutive rounds of proficiency testing, and received endorsement by First Pediatrics Medical Group. Doubling the number of clinics in the nationwide network is expected to be an important driver of 2019 revenues and earnings. 

CEO Rene Schena states, “Our finger stick allergy testing services provide the speed, accuracy, sensitivity and ease of administration to advance personalized- and precision-based medicine approaches to the doctor-prescribed management of allergy and asthma. Doubling Arrayit’s nationwide network in six months is consistent with the significant value proposition afforded by our innovative, non-invasive technology and fully automated, physician-friendly system for allergy test ordering and reporting.” 

About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve human health and wellness. Please visit www.arrayit.com for more information.

Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.

CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com

CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com

Arrayit-Corporation-Logo.jpg


ę GlobeNewswire 2019
All news about ARRAYIT CORPORATION
2020COVID-19 : Weekly Oversight And Enforcement Report—Week Of October 1, 2020
AQ
2020ARRAYIT : SEC Charges Top Executive of California Microcap Company for Misleading Claims C..
AQ
2020ARRAYIT : DOJ Announces Criminal Charges Against Lab Executive Accused Of Fraudulently Pro..
AQ
2020ARRAYIT : California tech CEO charged in coronavirus test fraud case
AQ
2019Arrayit Corporation Approved as New Medicare Part B Healthcare Provider for Allergy Tes..
GL
2019Arrayit Corporation Receives Approval as New Medicare Part B Healthcare Provider for Al..
CI
2019Arrayit Corporation Announces Global Expansion of Finger Stick Health and Wellness Test..
GL
2019Arrayit Corporation Announces Global Expansion of Finger Stick Health and Wellness Test..
CI
2019Arrayit Corporation Announces Allergy Testing Services Network Expansion to Multiple Cl..
GL
2019Arrayit Corporation Announces Allergy Testing Services Network Expansion to Multiple Cl..
CI
More news
Chart ARRAYIT CORPORATION
Duration : Period :
Arrayit Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Rene A. Schena Chairman & Chief Executive Officer
Mark Schena President, Secretary & Director
Todd J. Martinsky Director, Chief Technology Officer & EVP
Sector and Competitors
1st jan.Capi. (M$)
ARRAYIT CORPORATION-99.86%0
SARTORIUS AG37.97%39 650
BIOTAGE AB (PUBL)88.49%1 794
REVENIO GROUP OYJ6.26%1 601
VAREX IMAGING CORPORATION69.48%1 131
CELLAVISION AB (PUBL)4.82%827